The prevalence of chronic heart failure (CHF) in the general population is gradually
increasing mainly due to prolonged life expectancy of the general population and effective
interventional and medical treatment of acute cardiac syndromes. Even though in-hospital
survival has improved, the evolution towards CHF is documented approximately in 5%
of patients with recent acute syndromes, rising up to 10% when considering elderly
people [
1
,
2
,
3
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence of heart failure observed in emergency departments, ambulatory clinics, and hospitals.Am J Cardiol. 2018; 11: 1328-1335https://doi.org/10.1016/j.amjcard.2018.02.014
- Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.Eur J Heart Fail. 2019; 21: 1306-1325https://doi.org/10.1002/ejhf.1594
- Prognostic impact of comorbidities in hospitalized patients with acute exacerbation of chronic heart failure.Eur J Intern Med. 2016; 34: 63-67https://doi.org/10.1016/j.ejim.2018.11.002
- Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure.Circulation. 1993; 87: 70-75https://doi.org/10.1161/01.cir.87.1.70
- PARADIGM-HF investigators and committees. angiotensin-neprilysin inhibition versus enalapril in heart failure.N Engl J Med. 2014; 371: 993-1004https://doi.org/10.1056/NEJMoa1409077
- The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.Eur Heart J. 2018; 39: 1794-1798https://doi.org/10.1093/eurheartj/ehx679
- Clinical outcomes in patients with acute decompensated heart failure randomly assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF trial.Circulation. 2019; 139: 2285-2288https://doi.org/10.1161/CIRCULATIONAHA.118.039331
- Early effects of Sacubitril/Valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction.J Clin Med. 2019; 8 (pii): E262https://doi.org/10.3390/jcm8020262
- 2- and 3-Dimensional myocardial strain in cardiac health and disease.JACC Cardiovasc Imaging. 2019; 12: 1849-1863https://doi.org/10.1016/j.jcmg.2019.01.044
- Sacubitril/valsartan and short-term changes in the 6-minute walk test: a pilot study.Int J Cardiol. 2018; 252: 136-139https://doi.org/10.1016/j.ijcard.2017.10.074
Article info
Publication history
Published online: February 20, 2020
Accepted:
February 11,
2020
Received in revised form:
February 4,
2020
Received:
January 13,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
